Oct 05, 2018
Global Atopic Dermatitis Market and Competitive Landscape Report 2018
Oct 03, 2018
DS Biopharma Announces Positive Top-line Phase 2b Trial Results for Ds107 As a Topical Treatment for Mild to Moderate Atopic Dermatitis
Sep 15, 2018
Positive Phase 3 Results Presented for Dupixent® (dupilumab) Show Significant Improvement on Multiple Measures of Disease Severity in Adolescents with Moderate-to-Severe Atopic Dermatitis
Jul 25, 2018
Epiomic Epidemiology Report: Atopic Dermatitis Forecast In 21 Major Markets 2018-2028
Jul 10, 2018
Realm Therapeutics Announces Publication of Pre-Clinical Study Demonstrating Comparable Activity of PR022 and Topical Tofacitinib in the Treatment of Atopic Dermatitis
Jun 19, 2018
Dermavant to Present at JMP Securities Life Science Conference
May 24, 2018
Realm Therapeutics Completes Enrollment in Phase 2 Study of PR022 for Atopic Dermatitis
May 17, 2018
Glenmark Pharmaceuticals Announces Oral Presentation of New Data on GBR 830, an Investigational, Anti-OX40 Monoclonal Antibody, at the International Investigative Dermatology Meeting
May 16, 2018
Dupixent® (dupilumab) showed positive Phase 3 results in adolescents with inadequately controlled moderate-to-severe atopic dermatitis
May 03, 2018
Sanofi/Regeneron's Dupixent, the Darling of Atopic Dermatitis
Apr 16, 2018
Glenmark Pharmaceuticals Announces Initiation of a Phase 2b Trial of GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis
Mar 12, 2018
Realm Therapeutics Provides Clinical Update, including Results from a Phase 2 Study of PR013 in Allergic Conjunctivitis
Mar 02, 2018
FDA to Review DUPIXENT® (dupilumab) as Potential Treatment for Moderate-to-Severe Asthma
Feb 27, 2018
Realm Therapeutics Strengthens its Patent Portfolio with Two New USPTO Notice of Allowances
Feb 21, 2018
Canadian living with severe skin condition to shake a lifetime's worth of hands
Feb 17, 2018
AbbVie Presents New Late-Breaking Phase 2b Data on Upadacitinib in Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Feb 16, 2018
Glenmark Pharmaceuticals Presents New Data on GBR 830, a First-in-Class, Investigational, Anti-OX40 Monoclonal Antibody for the Treatment of Moderate-to-Severe Atopic Dermatitis at the 2018 American Academy of Dermatology Annual Meeting
Feb 15, 2018
Realm Therapeutics Highlights Strong 2017 Performance and Outlines 2018 Milestones
Feb 08, 2018
First targeted treatment for adults with moderate-to-severe atopic dermatitis, Dupixent(TM), now available in Canada
Feb 02, 2018
Growth of Sanofi-Regeneron's Dupixent in Atopic Dermatitis May Be Facing Its First Plateau, while Pfizer's Eucrisa Carves a Niche with Younger Patients